Weight loss as new diabetes target could boost sales of Novo Nordisk's obesity drug
Lasting weight loss should be the primary treatment target for people with type 2 diabetes, according to several researchers. Novo Nordisk, which has recently launched Wegovy, a drug that can lead to weight loss of up to 17 percent on average, agrees with the assessment.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
Wallets at Novo Nordisk might get fatter if enduring weight loss becomes the primary treatment goal for people with type 2 diabetes, as several researchers have proposed in the Lancet, Danish business daily Børsen reports on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
Novo Nordisk starts crucial trial of obesity tablet
For subscribers
